Bolin Geng on discovery medicinal chemistry

Personal opinions

Thursday, September 1, 2022

Beta-Lactamase Inhibitors

From my early work on Penicillin-based Sulfones (SMU, BMCL, 1995, 5, 1513-18, ) to the more recent DABCO Durlobactam (AZD2514/ETX2514) (AstraZeneca, WO2013150296 (US 9,309,245, US 9,623,014)— a full circle!

Posted by Bolin Geng at 4:37 PM No comments:

Newer Posts Older Posts Home

Subscribe to: Posts (Atom)

About Me

Bolin Geng: Bolin is a drug discovery and development professional with over 25 years of experience in the pharma industry. He recently served as Vice President, Head of Chemistry at Myrobalan Therapeutics, a pharmaceutical company focused on developing novel therapeutics for the treatment of CNS diseases. Before joining Myrobalan, he was Vice President, Head of Research at LEAF4Life. Prior to LEAF4Life, Bolin held roles at several pharma companies, including AstraZeneca. Bolin has made significant contributions to drug discovery and development throughout his career. He is an inventor of over 10 drug candidates, of which 5 have entered clinical development, including XacDuro® (Sul-Dur), an antibacterial agent whose New Drug Application (NDA) was approved in 2023. He also contributed to the development of Onivyde®, an FDA-approved (2015) anticancer drug. Bolin has published over 30 peer-reviewed articles and is an inventor/co-inventor of over 200 granted patents and patent applications. Bolin received his PhD in Organic Chemistry from the University of Montpellier, France.

View my complete profile

Blog Archive

May 2023 (1)
January 2023 (1)
September 2022 (1)
August 2022 (1)
May 2021 (1)
August 2019 (1)
July 2019 (1)
February 2019 (1)
September 2016 (1)
August 2015 (1)
April 2015 (1)
February 2015 (1)
January 2015 (2)
January 2010 (1)
December 2009 (3)
April 2007 (1)

Picture Window theme. Theme images by GP232. Powered by Blogger.